{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:47:23Z","timestamp":1769917643774,"version":"3.49.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Atrial fibrillation is the most common sustained cardiac arrhythmia in the general population. In western countries with aging populations, atrial fibrillation poses a significant health concern, as it is associated with a high risk of thromboembolism, stroke, congestive heart failure, and myocardial infarction. Thrombi are generated in the left atrial appendage, and subsequent embolism into the cerebral circulation is a major cause of ischemic stroke. Therefore, patients have a lifetime risk of stroke, and those at high risk, defined as a CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc2 (congestive heart failure, hypertension, age &gt;75 years, diabetes mellitus, stroke\/transient ischemic attack\/thromboembolism, vascular disease, age 65-74 yrs, sex category) \u22652, are usually placed on oral anticoagulants. Unfortunately, long-term anticoagulation poses bleeding risks, of which intracranial hemorrhage (ICH) is the most feared and deadly complication.<\/jats:p>\n          <jats:p>In patients who survive an ICH, the question of oral anticoagulation resumption arises. It is a therapeutic dilemma in which clinicians must decide how to manage the risk of thromboembolism versus recurrent hemorrhage. Although there is a substantial amount of retrospective data on the topic of resumption of anticoagulation, there are, at this time, no randomized controlled trials addressing the issue. We therefore sought to address ICH risk and management, summarize high quality existing evidence on restarting oral anticoagulation, and suggest an approach to clinical decision-making.<\/jats:p>","DOI":"10.1097\/crd.0000000000000288","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:44:28Z","timestamp":1580132668000},"page":"190-196","source":"Crossref","is-referenced-by-count":10,"title":["Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After an Intracranial Hemorrhage"],"prefix":"10.1097","volume":"28","author":[{"given":"Nhi Y.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Medicine, California Pacific Medical Center, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bmj.38698.709572.55","article-title":"Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.","volume":"332","author":"Choudhry","year":"2006","journal-title":"BMJ"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.amjmed.2005.09.052","article-title":"Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics.","volume":"119","author":"Choudhry","year":"2006","journal-title":"Am J Med"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0149-2918(03)80167-4","article-title":"Factors influencing physicians\u2019 reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey.","volume":"25","author":"Gross","year":"2003","journal-title":"Clin Ther"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R5-20230903","first-page":"195","article-title":"Atrial fibrillation: the current epidemic.","volume":"14","author":"Morillo","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral Anticoagulation and functional outcome after intracerebral hemorrhage.","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1161\/01.STR.0000078311.18928.16","article-title":"Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis.","volume":"34","author":"Eckman","year":"2003","journal-title":"Stroke"},{"issue":"suppl 2","key":"R8-20230903","first-page":"S3","article-title":"Primary intracerebral hemorrhage: pathophysiology.","volume":"32","author":"Auer","year":"2005","journal-title":"Can J Neurol Sci"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/01.STR.19.5.547","article-title":"The stroke data bank: design, methods, and baseline characteristics.","volume":"19","author":"Foulkes","year":"1988","journal-title":"Stroke"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1161\/STROKEAHA.109.559450","article-title":"Cerebral microbleeds in ischemic stroke patients on warfarin treatment.","volume":"40","author":"Orken","year":"2009","journal-title":"Stroke"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5853\/jos.2016.00864","article-title":"Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update.","volume":"19","author":"An","year":"2017","journal-title":"J Stroke"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1212\/WNL.47.2.405","article-title":"Incidence of spontaneous intracerebral hemorrhage among hispanics and non-hispanic whites in New Mexico.","volume":"47","author":"Bruno","year":"1996","journal-title":"Neurology"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage.","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/aje\/kwh225","article-title":"Excess stroke in Mexican Americans compared with non-hispanic whites: the brain attack surveillance in corpus christi project.","volume":"160","author":"Morgenstern","year":"2004","journal-title":"Am J Epidemiol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11886-014-0480-9","article-title":"Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?","volume":"16","author":"Hankey","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.","volume":"129","author":"Lopes","year":"2017","journal-title":"Blood"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2214-109X(13)70089-5","article-title":"Global and regional burden of ischaemic and hemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.","volume":"1","author":"Krishnamurthi","year":"2013","journal-title":"Lancet Glob Health"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages.","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(18)31878-6","article-title":"Intracerebral haemorrhage: current approaches to acute management.","volume":"392","author":"Cordonnier","year":"2018","journal-title":"Lancet"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the rra of reversal agents.","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","article-title":"Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis.","volume":"262","author":"Caldeira","year":"2015","journal-title":"J Neurol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study \u2013.","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"R30-20230903","first-page":"731","article-title":"Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism.","volume":"9","author":"Schulman","year":"2011","journal-title":"JTH"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/00015458.2005.11679715","article-title":"Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation.","volume":"105","author":"De Vleeschouwer","year":"2005","journal-title":"Acta Chir Belg"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage.","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nrl.2011.04.020","article-title":"[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].","volume":"27","author":"Vidal-Jordana","year":"2012","journal-title":"Neurologia"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archneur.65.10.1313","article-title":"Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage.","volume":"65","author":"Claassen","year":"2008","journal-title":"Arch Neurol"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cjca.2011.10.002","article-title":"Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study.","volume":"28","author":"Yung","year":"2012","journal-title":"Can J Cardiol"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a Nationwide Cohort Study.","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation.","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/STROKEAHA.116.012945","article-title":"Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage.","volume":"47","author":"Ottosen","year":"2016","journal-title":"Stroke"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","article-title":"Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.","volume":"66","author":"Davis","year":"2006","journal-title":"Neurology"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.STR.0000258078.35316.30","article-title":"Determinants of intracerebral hemorrhage growth: an exploratory analysis.","volume":"38","author":"Broderick","year":"2007","journal-title":"Stroke"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/01.wnl.0000257087.22852.21","article-title":"Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage.","volume":"68","author":"Goldstein","year":"2007","journal-title":"Neurology"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/01.STR.0000149615.51204.0b","article-title":"Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage.","volume":"36","author":"Silva","year":"2005","journal-title":"Stroke"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/01.STR.27.10.1783","article-title":"Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course.","volume":"27","author":"Kazui","year":"1996","journal-title":"Stroke"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","article-title":"Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.","volume":"26","author":"Hart","year":"1995","journal-title":"Stroke"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine.","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/imj.12034","article-title":"Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates.","volume":"43","author":"Hanger","year":"2013","journal-title":"Intern Med J"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12028-014-9972-0","article-title":"Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.","volume":"21","author":"Frontera","year":"2014","journal-title":"Neurocrit Care"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"e0137444","DOI":"10.1371\/journal.pone.0137444","article-title":"Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis.","volume":"10","author":"Skaistis","year":"2015","journal-title":"PLoS One"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor xa inhibitors.","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"11S","key":"R54-20230903","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.amjmed.2016.06.009","article-title":"Preclinical and clinical data for factor Xa and \u201cuniversal\u201d reversal agents.","volume":"129","author":"Milling","year":"2016","journal-title":"Am J Med"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3949\/ccjm.77a.10018","article-title":"Should anticoagulation be resumed after intracerebral hemorrhage?","volume":"77","author":"Goldstein","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"R57-20230903","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12028-008-9134-3","article-title":"Risk of thromboembolism following acute intracerebral hemorrhage.","volume":"10","author":"Goldstein","year":"2009","journal-title":"Neurocrit Care"},{"key":"R58-20230903","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the swedish atrial fibrillation cohort study.","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"key":"R59-20230903","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review.","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"R60-20230903","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"R61-20230903","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.56.6.773","article-title":"Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage.","volume":"56","author":"Bailey","year":"2001","journal-title":"Neurology"},{"key":"R62-20230903","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"R63-20230903","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1161\/01.STR.0000080678.09344.8D","article-title":"Risk factors for intracerebral hemorrhage in the general population: a systematic review.","volume":"34","author":"Ariesen","year":"2003","journal-title":"Stroke"},{"key":"R64-20230903","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1212\/WNL.0000000000003952","article-title":"Alcohol use and risk of intracerebral hemorrhage.","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"R65-20230903","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","article-title":"Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.","volume":"36","author":"Hart","year":"2005","journal-title":"Stroke"},{"key":"R66-20230903","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1161\/STROKEAHA.117.017072","article-title":"Genetics of spontaneous intracerebral hemorrhage.","volume":"48","author":"Falcone","year":"2017","journal-title":"Stroke"},{"key":"R67-20230903","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/STROKEAHA.111.000038","article-title":"Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts.","volume":"44","author":"Charidimou","year":"2013","journal-title":"Stroke"},{"key":"R68-20230903","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2010.03882.x","article-title":"Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk.","volume":"8","author":"Hawryluk","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R69-20230903","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation.","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"key":"R70-20230903","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000094831","article-title":"Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee.","volume":"22","author":"Steiner","year":"2006","journal-title":"Cerebrovasc Dis"},{"key":"R71-20230903","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"R72-20230903","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s13063-015-0898-4","article-title":"Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.","volume":"16","author":"van Nieuwenhuizen","year":"2015","journal-title":"Trials"},{"key":"R74-20230903","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/CRD.0000000000000118","article-title":"Reversal agents for direct oral anticoagulants: understanding new and upcoming options.","volume":"24","author":"Rogers","year":"2016","journal-title":"Cardiol Rev"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:30:03Z","timestamp":1693733403000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000288","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}